AbbVie (ABBV) Now Third Large-Cap Interested in SHP2, Watch BridgeBio Pharma (BBIO) Says Mizuho
Tweet Send to a Friend
Mizuho Securities analyst Salim Syed reiterated a Buy rating and $51.00 price target on BridgeBio Pharma (NASDAQ: BBIO) after AbbVie ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
